JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2014, Vol. 52 ›› Issue (7): 50-55.doi: 10.6040/j.issn.1671-7554.0.2014.002

Previous Articles     Next Articles

Expression of GRK6 in gastric carcinoma and its prognostic value

ZHANG Zheng, SHEN Hongchang, FU Guobin, ZHANG Jianchao, WANG Weibo   

  1. Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China
  • Received:2014-01-02 Revised:2014-06-12 Online:2014-07-10 Published:2014-07-10

PDF (PC)

174

Abstract: Objective To investigate the expression of G protein coupled receptor kinase 6 (GRK6) in gastric carcinoma in order to examine its correlation with the clinicopathologial parameters and prognosis of gastric cancer. Methods GRK6 expressions in 132 malignant gastric carcinoma cases and 8 benign cases were detected with tissue microarray and immunohistochemistry technique. Relevant factors influencing GRK6 expression were analyzed statistically. Association between GRK6 expression and prognosis of gastric cancer was evaluated with reference to follow-up data. Results The high expression rate of GRK6 in gastric carcinoma was 49.17%, and the low expression rate was 50.83%. Multivariate logistic regression analysis disclosed that there was correlation between GRK6 expression and poor differentiation (P<0.05). The 5-year overall survival rates of patients with high and low GRK6 expressions were 28.81% and 67.21%, respectively (P<0.05). Multivariate Cox regression analysis showed that GRK6 was an independent prognostic factor of gastric cancer (P<0.05). Conclusion GRK6 expression in gastric carcinoma is significantly higher than in benign cases. The overexpression of GRK6 is closely correlated with histological differentiation. GRK6 may play an important role in the occurrence and development of gastric carcinoma.

Key words: Stomach neoplasm, Tissue microarray, Prognosis, G protein coupled receptor kinase 6, Immunohistochemistry

CLC Number: 

  • R735.2
[1] Jemal A, Siegel R, Ward E, et al. Cancer statistics 2008[J]. CA Cancer J Clin, 2008, 58(4):71-96.
[2] Roder D M, Kelley J R, Duggan J M. Gastric cancer epidemiology and risk factors[J]. J Clin Epidemiol, 2003, 56(1):1-9.
[3] Pitcher J A, Freedman N J, Lefkowitz R J. G protein-coupled receptor kinases[J]. Annurev Biochem, 1998, 67(1):653-692.
[4] Premont R T. Once and future signaling:G protein-coupled receptor kinase control of neuronal sensitivity[J]. Neuromolecular Med, 2005, 7(1-2):129-147.
[5] Claing A, Laporte S A, Caron M G, et al. Endocytosis of G protein-coupled receptors:roles of G protein-coupled receptor kinases and beta-arrestin proteins[J]. Prog Neurobiol, 2002, 66(2):61-79.
[6] Lymperopoulos A, Bathgate A. Pharmacogenomics of the heptahelical receptor regulators G-protein-coupled receptor kinases and arrestins:the known and the unknown[J]. Pharmacogenomics, 2012, 13(3):323-341.
[7] Raghuwanshi S K, Smith N, Rivers E J, et al. G protein-coupled receptor kinase 6 deficiency promotes angiogenesis, tumor progression, and metastasis[J]. J Immunol, 2013, 190(10):5329-5336.
[8] Tiedemann R E, Zhu Y X, Schmidt J, et al. Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6[J]. Blood, 2010, 115(8):1594-1604.
[9] Li Y P. GRK6 expression in patients with hepatocellular carcinoma[J]. Asian Pac J Trop Med, 2013, 6(3):220-223.
[10] Kononen J, Bubendortf L, Kallioniemi A, et al. Tissue microarrays for high through put molecular profiling of tumor specimens[J]. Nat Med, 1998, 4(7):844-847.
[11] Métayé T, Gibelin H, Perdrisot R, et al. Pathophysiological roles of G-protein-coupled receptor kinases[J]. Cell Signal, 2005, 17(8):917-928.
[12] Hupfeld C J, Olefsky J M. Regulation of receptor tyrosine kinase signaling by GRKs and beta-arrestins[J]. Annu Rev Physiol, 2007, 69:561-577.
[13] Cipolletta E, Campanile A, Santulli G, et al. The G protein coupled receptor kinase 2 plays an essential role in beta-adrenergic receptor-induced insulin resistance[J]. Cardiovasc Res, 2009, 84(3):407-415.
[14] Penela P, Murga C, Ribas C, et al. The complex G protein-coupled receptor kinase 2 (GRK2) interactome unveils new physiopathological targets[J]. Br J Pharmacol, 2010, 160(4):821-832.
[15] Martini J S, Raake P, Vinge L E, et al. Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes[J]. Proc Natl Acad Sci USA, 2008, 105(34) :12457-12462.
[16] Woerner B M, Luo J, Brown K R, et al. Suppression of G-protein-coupled receptor kinase 3 expression is a feature of classical GBM that is required for maximal growth[J]. Mol Cancer Res, 2012, 10(1):156-166.
[17] Métayé T, Menet E, Guilhot J, et al. Expression and activity of G protein-coupled receptor kinases in differentiated thyroid carcinoma[J]. J Clin Endocrinol Metab, 2002, 87(7):3279-3286.
[18] Kim J I, Chakraborty P, Wang Z, et al. G-protein coupled receptor kinase 5 regulates prostate tumor growth[J]. J Urol, 2012, 187(1):322-329.
[19] Wu C C, Tsai F M, Shyu R Y, et al. G protein-coupled receptor kinase 5 mediates Tazarotene-induced gene 1-induced growth suppression of human colon cancer cells[J]. BMC Cancer, 2011, 11:175. doi:10.1186/1471-2407-11-175.
[20] Wei Z, Hurtt R, Ciccarelli M, et al. Growth inhibition of human hepatocellular carcinoma cells by overexpression of G protein-coupled receptor kinase2[J]. J Cell Physiol, 2012, 227(6):2371-2377.
[1] LI Yinglin, SONG Daoqing, XU Zhonghua. Identification of FKBP11 expression in clear cell renal cell carcinoma using bioinformatics analysis [J]. Journal of Shandong University (Health Sciences), 2020, 1(9): 45-51.
[2] SHI Shuang, LI Juan, MI Qi, WANG Yunshan, DU Lutao, WANG Chuanxin. Construction and application of a miRNAs prognostic risk assessment model of gastric cancer [J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 47-52.
[3] LI Xingkai, LIU Zhanye, JIANG Yunfeng, LI Jun. Clinicopathological factors and prognosis between primary central and peripheral lung squamous cell carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(9): 73-78.
[4] NIE Siyue, WANG Zhen, SUN Jingyu, LIU Jie, LI Juan, WEI Xiaojuan, LU Chunxiao, L(¨overU)Xingyan, WANG Shuyun, SUN Yuping. Expression and clinical significance of angiopoietin-like protein 5 in human gastric cancer tissues [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(8): 61-65.
[5] ZONG Shuai, XIAO Dongjie, LIU Hua, JIA Yanfei, MA Xiaoli, LI Huanjie, LI Ping, ZHENG Yan, WANG Yunshan. Expression of CSN5 and its correlation with the prognosis of gastric carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(7): 12-16.
[6] SUN Qijing, CHEN Fangfang, LI Chunxiao, ZHANG Caiqing. Clinical value of PNI and HGB in evaluating the prognosis of the middle to late stage non-small cell lung cancer patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(4): 55-59.
[7] WANG Yongqiang, ZHANG Weiquan, SUN Qifeng, DONG Xiaopeng, PENG Chuanliang, ZHANG Yuan, ZHAO Xiaogang. Expression and significance of CK14 in non-small cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(3): 83-87.
[8] LIN Jiaxiang, GUO Zijia, SU Peng, WANG Xiao, GUO Yaxin, WU Xiaojuan, XIANG Lei, ZHOU Zhiqiang, WANG Yan, CUI Xiujie, PAN Aifeng, GUO Chenghao. The role of CIP2A in the transformation of breast ductal epithelium and prognosis of invasive breast cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(3): 100-106.
[9] ZHOU Lanlan, PAN Xueyi, GUO Yu. Clinical characteristics and prognosis of 48 patients with mixed phenotype acute leukemia [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(2): 79-83.
[10] ZHANG Xiying, ZHAI Chunyan, LI Jingsong, HAN Bo. Expression of EZH2 in Chinese Ewing sarcoma patients and its relationship with clinicopathological parameters and prognosis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(2): 84-91.
[11] LIU Huiling, WANG Xingwen, FENG Shaobin, FENG Hong, HAN Junqing. Association between high expression of scavenger receptor class B type I and the prognosis of colon cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(10): 84-89.
[12] LI Xiaoning, CUI Lianqun. Treatment timing of non-infarct-related artery in patients with multi-vessel disease and acute myocardial infarction [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(8): 50-54.
[13] WANG Wen, LIU Yao, LONG Fei, MA Weixia, SU Lili. Correlation between lymphocyte-to-monocyte ratio in peripheral blood and prognosis of malignant pleural mesothelioma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(8): 72-77.
[14] LIU Tong, ZHANG Xin, WANG Chuanxin. Significance of IRX5 mRNA in the diagnosis and prognosis of colorectal cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(7): 69-74.
[15] MA Lin, ZHANG Dong, TANG Lei, YE Siyuan, YAN Chuanzhu, CAO Lili. Prognostic hematological biomarkers of amyotrophic lateral sclerosis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(4): 46-50.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd